Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Oncogenuity and Tamid - Narrative) (Details)

v3.21.1
Licenses Acquired (Oncogenuity and Tamid - Narrative) (Details)
12 Months Ended
May 06, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development - licenses acquired   $ 2,834,000 $ 6,090,000
Oncogenuity [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development - licenses acquired   271,000 0
Licensing Agreements [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Upfront fees payment $ 300,000    
Common shares issued (in shares) | shares 1,000,000    
Amount of net of debt utilized   21,000  
Research and development - licenses acquired   300,000  
Licensing Agreements [Member] | Tamid [Member] | University of North Carolina [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development - licenses acquired   $ 0 $ 0
Licensing Agreements [Member] | Discount for Lack of Marketability [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Common Shares, measurement input     0.417
Licensing Agreements [Member] | Measurement Input Weighted Average Cost of Capital [ Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Common Shares, measurement input     0.205
Licensing Agreements [Member] | Share Price [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Common Shares, measurement input | $ / shares   0.021  
Licensing Agreements [Member] | Completion of Clinical Development Milestones [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Payments of milestones $ 15,300,000    
Licensing Agreements [Member] | Achievement of Certain Sales Milestones [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Payments of milestones 15,000,000.0    
Licensing Agreements [Member] | Certain Milestones in Connection with the Initial Indication [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Payments of milestones $ 18,000,000.0    
Oncogenuity [Member] | Licensing Agreements [Member] | Oncogenuity [Member] | Columbia University [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Percentage of ownership 10.00%